We demonstrated by Western blotting that LATS1, and not LATS2, was significantly decreased upon MG treatment (300 and 500 μM) in both glycolytic MDA-MB-231 and MDA-MB-468 and non-glycolytic MCF7 breast cancer cells (Figure 6B). The gene discussed is LATS1; the disease is breast carcinoma.